Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Bleeding Risk Reduction in Relation to Predicted Factor IX Levels in Hemophilia B Patients Receiving Idelvion (rIX-FP)

John Roberts, PhD, Cecilia Fosser, PhD, Michael Tortorici, PhD PharmD, Alex Veldman, MD, Iris C. Jacobs, MD, Jagdev Sidhu, PhD

Blood (2016) 128 (22): 1411.

https://doi.org/10.1182/blood.V128.22.1411.1411

Published: 2016

Journal Articles

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Claude Negrier, MD, Lynda Mae Lepatan, MD, Faralzah Karim, MD, Anne Lienhart, MD, Denise Wolko, Christine Voigt, PhD, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 2298.

https://doi.org/10.1182/blood.V126.23.2298.2298

Published: 2015

Journal Articles

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Aaron Lubetsky, MD, Uri Martinowitz, MD, Toshko Lissitchkov, MD, Christine Voigt, PhD, Denise Wolko, Iris C. Jacobs, MD, Elena Santagostino, MD PhD

Blood (2015) 126 (23): 1096.

https://doi.org/10.1182/blood.V126.23.1096.1096

Published: 2015

Journal Articles

Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B

Elena Santagostino, MD PhD, Christine Voigt, PhD, Denise Wolko, Grace Cole, Yanyan Li, PhD, Iris C. Jacobs, MD

Blood (2015) 126 (23): 548.

https://doi.org/10.1182/blood.V126.23.548.548

Published: 2015

Journal Articles

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Elena Santagostino, MD PhD, Iris C. Jacobs, MD, Christine Voigt, PhD, Annettee Feussner, PhD, Tharin Limsakun, PhD

Blood (2014) 124 (21): 1491.

https://doi.org/10.1182/blood.V124.21.1491.1491

Published: 2014

Journal Articles

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

Aaron Lubetsky, MD MSc, Toshko Lissitchkov, MD, Elena Santagostino, MD, PhD, Gantcho Jotov, MD, Tami Barazani-Brutman, Ph.D, Christine Voigt, Ph.D, Tina Moises, Ph.D, Iris C. Jacobs, MD, Uri Martinowitz, MD

Blood (2013) 122 (21): 1109.

https://doi.org/10.1182/blood.V122.21.1109.1109

Published: 2013

Journal Articles

Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)

Uriel Martinowitz, MD, Aaron Lubetsky, MD, Elena Santagostino, MD, PhD, Gantcho Jotov, MD, Jacob Luboshitz, MD, Shadan Lalezari, MD, Tami Barazani-Brutman, Ph.D, Christine Voigt, Ph.D, Tina Moises, Ph.D, Iris C. Jacobs, MD, Toshko Lissitchkov

Blood (2012) 120 (21): 1121.

https://doi.org/10.1182/blood.V120.21.1121.1121

Published: 2012

NARROW

Bleeding Risk Reduction in Relation to Predicted Factor IX Levels in Hemophilia B Patients Receiving Idelvion (rIX-FP)

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)

Email alerts

ASH Publications

American Society of Hematology

Bleeding Risk Reduction in Relation to Predicted Factor IX Levels in Hemophilia B Patients Receiving Idelvion (rIX-FP)

Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries

Long-Term Use of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B in the Prolong-9FP Program

Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B

Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only